Cancer Drug Design and Discovery

Cancer Drugs Success Resistance Crystallography Intellectual property Telomerase Pharmacokinetics Hormone therapy Metabolism DNA repair Regulation Oxidative stress Reverse transcriptase Apoptosis Inhibitors Pharmacogenomics Therapy Natural products Drug Resistance Glycolysis Protein-protein interaction Medicinal chemistry licensing Geldanamycin Bioactivity Fragments Calicheamicin Structure Based Design Telomeres Mechanisms Senescence G-quadruplexes Personalized therapy Androgen Hypoxia Tumor Suppressor p53 Biomarkers Anticancer agents MDM2 Companion Diagnostics Angiogenesis Therapeutic Prostate cancer Sorafenib Trial design Molecular Targets Cancer Drug Discovery Cancer treatment Vemurafenib Treatment-Resistance Clinical development Cancer therapy Tyrosine kinase Cell Targeting Inhibitor Structure-activity relationship (SAR) Cancer treatments Receptor Molecular medicine Molecular diversity Endpoints Inequitable conduct Abiraterone Adaptive licensing Anticancer medicines Anticancer activity and selectivity B-RAF kinase inhibitors Client protein degradation Clinical activity in breast and lung cancer Chemical tools District and Federal Courts Dual inhibitors CYP17 Cytotoxic drugs Duocarmycins enzyme inhibition DNA damage response (DDR) Drug discover Generic Challenge F14512 Hallmarks characteristics of cancer Dabrafenib DNA cytotoxics Intrinsic mitochondrial pathway Investigative combinations Extrinsic mitochondrial pathway MDM2-p53 interaction Gemtuzumab ozogamicin Obviousness Glutaminolysis nonsteroidal Molecular chaperone heat shock protein 90 (HSP90) Orphan indications Prosecution Laches Protein kinase B pediatric medicines radicicol inventorship Vintafolide Melanoma therapy organic synthesis Molecularly targeted therapy Second and subsequent indications PI3K kinase Pyrrolobenzodiazepine (PBD) dimers Small-molecule HSP90 inhibitors The Warburg effect Steroidal